Mesothelioma review.

W V Med J

Department of Pulmonary and Critical Care Medicine, West Virginia University Hospital, USA.

Published: June 2009

Malignant mesothelioma (MME) is an aggressive tumor of serosal surfaces resistant to current treatment options. MME is typically diagnosed in middle aged males exposed to asbestos in the workplace. However, MME is occasionally diagnosed at an earlier age without an obvious source of exposure. MME typically carries an average survival rate of six to thirteen months. A new treatment option, the trimodality approach, has recently been proclaimed as superior to standard treatment. Therefore, a case of a 38-year-old-female diagnosed with MME is reported to review its epidemiology, pathogenesis, clinical presentation, diagnostic modalities and most current treatment options.

Download full-text PDF

Source

Publication Analysis

Top Keywords

current treatment
8
treatment options
8
mme typically
8
mme
5
mesothelioma review
4
review malignant
4
malignant mesothelioma
4
mesothelioma mme
4
mme aggressive
4
aggressive tumor
4

Similar Publications

Effect of Capromorelin on Appetite and Weight Gain of Domestic Pigeons ().

J Avian Med Surg

January 2025

Department of Small Animal Medicine and Surgery (Zoological Medicine), University of Georgia College of Veterinary Medicine, Athens, GA 30602, USA,

Weight loss and decreased appetite are commonly encountered sequela of disease and stress in avian patients. However, there is currently minimal information in the veterinary literature regarding appetite stimulation in birds. Capromorelin is a potent agonist of the growth hormone secretagogue receptor and increases food consumption via direct stimulation of the hunger centers of the hypothalamus.

View Article and Find Full Text PDF

Contributors and Solutions to High Out-of-Pocket Costs for Heart Failure Medications.

J Am Coll Cardiol

December 2024

Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA; Adult and Child Center for Outcomes Research and Delivery Science, University of Colorado School of Medicine, Aurora, Colorado, USA.

As expensive therapeutics rise to the fore of heart failure management, out-of-pocket (OOP) medication costs have become increasingly relevant to patient care. Prescription medication costs influence medical decision-making and affect adherence. Yet, individualized cost estimates are seldom available during clinical encounters when prescription decisions are made.

View Article and Find Full Text PDF

Demographic-Based Personalized Left Ventricular Hypertrophy Thresholds for Hypertrophic Cardiomyopathy Diagnosis.

J Am Coll Cardiol

December 2024

Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.

Background: Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death. Current diagnosis emphasizes the detection of left ventricular hypertrophy (LVH) using a fixed threshold of ≥15-mm maximum wall thickness (MWT). This study proposes a method that considers individual demographics to adjust LVH thresholds as an alternative to a 1-size-fits-all approach.

View Article and Find Full Text PDF

Smart Cell Therapy: an industry perspective on macrophages as living drugs.

Cytotherapy

December 2024

Barcia Novel Therapies, Lexington, Massachusetts, USA. Electronic address:

Macrophage-based cell therapies represent a cutting-edge frontier in immunotherapy, offering distinct advantages over conventional approaches like CAR-T. This review explores the potential of macrophages to orchestrate both innate and adaptive immune responses, enhancing the body's ability to combat diseases locally and systemically. Dubbed a "Smart Cell Therapy," macrophages can initiate and coordinate complex immunological cascades, leveraging multiple immune system components while also performing effector functions.

View Article and Find Full Text PDF

Rectangular Repetitive Transcranial Magnetic Monophasic vs Biphasic Stimulation for Major Depressive Disorder: A Randomized Controlled Pilot Trial.

Neuromodulation

January 2025

Department of Psychiatry and Behavioral Sciences, Division of Child and Adolescent Psychiatry, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.

Objectives: Biphasic sinusoidal repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation treatment that has been approved by the US Food and Drug Administration for treatment-resistant depression (TRD). Recent advances suggest that standard rTMS may be improved by altering the pulse shape; however, there is a paucity of research investigating pulse shape, owing primarily to the technologic limitations of currently available devices. This pilot study examined the feasibility, tolerability, and preliminary efficacy of biphasic and monophasic rectangular rTMS for TRD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!